Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749359 · ClinicalTrials.gov registry record · Phase 1
PAXIL CR Bioequivalence Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
NCT00749359: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT00749359 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 166 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00749359, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
Study Summary
This study is to determine if controlled release paroxetine tablets manufactured at two different sites behave similarly in healthy volunteers.
Interventions
- DRUG Paxil CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2008-07-07 |
| Est. Completion | 2008-09-16 |
| Phase | Phase 1 |
What the finished NCT00749359 record still lists
NCT00749359 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 1 intervention - of which Paxil CR is the first listed.
NCT00749359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00749359 about?
NCT00749359 is a clinical study titled "PAXIL CR Bioequivalence Study". This study is to determine if controlled release paroxetine tablets manufactured at two different sites behave similarly in healthy volunteers.
What is the current status of trial NCT00749359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2008-07-07. Estimated completion is 2008-09-16.
What interventions are being tested in trial NCT00749359?
The interventions under investigation include: Paxil CR (DRUG).
Who is sponsoring clinical trial NCT00749359?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00749359's enrollment target sits among peer trials
166 330th of 2000 higher than 1,669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI